Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nusrat Harun

Showing results (31-40 of 43) with videos related to

Pageof 5
Sort By:
Respiratory Investigation|January 11, 2024
Safety and efficacy of sirolimus in hospitalised patients with COVID-19 pneumoniaAbhishek Singla, Nusrat Harun, Daniel F Dilling, et al.
Head & Neck|December 18, 2018
PI3-kinase pathway biomarkers in oral cancer and tumor immune cellsMohammad Y Ibrahim, Maria I Nunez, Nusrat Harun, et al.
Annals of Diagnostic Pathology|April 22, 2014
Elevated PDGFRB gene copy number gain is prognostic for improved survival outcomes in resected malignant pleural mesotheliomaAnne S Tsao, Nusrat Harun, Junya Fujimoto, et al.
Journal of Surgical Oncology|December 13, 2019
Residual tumor volume discriminates prognosis after surgery for neuroendocrine liver metastasisYosuke Kasai, Kenzo Hirose, Carlos U Corvera, et al.
Stroke|January 25, 2011
Pharmacological deep vein thrombosis prophylaxis does not lead to hematoma expansion in intracerebral hemorrhage with intraventricular extensionTzu-Ching Wu, Mallik Kasam, Nusrat Harun, et al.
The Oncologist|August 30, 2014
A phase I/II study combining erlotinib and dasatinib for non-small cell lung cancerKathryn A Gold, J Jack Lee, Nusrat Harun, et al.
Cancer Research Communications|May 16, 2025
Phase II Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Patients with Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaOlga Zamulko, Vidhya Karivedu, Muhammad Kashif Riaz, et al.
Oral Oncology|June 19, 2018
Randomized phase II trial of cixutumumab alone or with cetuximab for refractory recurrent/metastatic head and neck squamous cell carcinomaRenata Ferrarotto, William N William, Jennifer E Tseng, et al.
Biorxiv : the Preprint Server for Biology|December 11, 2023
GABA(A) receptor activation drives GABARAP-Nix mediated autophagy to radiation-sensitize primary and brain-metastatic lung adenocarcinoma tumorsDebanjan Bhattacharya, Riccardo Barille, Donatien Kamdem Toukam, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 2, 2022
Phase II Trial of Adjuvant Nivolumab Following Salvage Resection in Patients with Recurrent Squamous Cell Carcinoma of the Head and NeckJennifer L Leddon, Shuchi Gulati, Sulsal Haque, et al.
Pageof 5

Showing results (31-40 of 43) with videos related to

Sort By:
Pageof 5
Respiratory Investigation|January 11, 2024
Safety and efficacy of sirolimus in hospitalised patients with COVID-19 pneumoniaAbhishek Singla, Nusrat Harun, Daniel F Dilling, et al.
Head & Neck|December 18, 2018
PI3-kinase pathway biomarkers in oral cancer and tumor immune cellsMohammad Y Ibrahim, Maria I Nunez, Nusrat Harun, et al.
Annals of Diagnostic Pathology|April 22, 2014
Elevated PDGFRB gene copy number gain is prognostic for improved survival outcomes in resected malignant pleural mesotheliomaAnne S Tsao, Nusrat Harun, Junya Fujimoto, et al.
Journal of Surgical Oncology|December 13, 2019
Residual tumor volume discriminates prognosis after surgery for neuroendocrine liver metastasisYosuke Kasai, Kenzo Hirose, Carlos U Corvera, et al.
Stroke|January 25, 2011
Pharmacological deep vein thrombosis prophylaxis does not lead to hematoma expansion in intracerebral hemorrhage with intraventricular extensionTzu-Ching Wu, Mallik Kasam, Nusrat Harun, et al.
The Oncologist|August 30, 2014
A phase I/II study combining erlotinib and dasatinib for non-small cell lung cancerKathryn A Gold, J Jack Lee, Nusrat Harun, et al.
Cancer Research Communications|May 16, 2025
Phase II Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Patients with Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaOlga Zamulko, Vidhya Karivedu, Muhammad Kashif Riaz, et al.
Oral Oncology|June 19, 2018
Randomized phase II trial of cixutumumab alone or with cetuximab for refractory recurrent/metastatic head and neck squamous cell carcinomaRenata Ferrarotto, William N William, Jennifer E Tseng, et al.
Biorxiv : the Preprint Server for Biology|December 11, 2023
GABA(A) receptor activation drives GABARAP-Nix mediated autophagy to radiation-sensitize primary and brain-metastatic lung adenocarcinoma tumorsDebanjan Bhattacharya, Riccardo Barille, Donatien Kamdem Toukam, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 2, 2022
Phase II Trial of Adjuvant Nivolumab Following Salvage Resection in Patients with Recurrent Squamous Cell Carcinoma of the Head and NeckJennifer L Leddon, Shuchi Gulati, Sulsal Haque, et al.
Pageof 5